Caitlin M Peterman1,2,3, R Dawn Fevurly3,4,5, Ahmad I Alomari3,6, Cameron C Trenor3,7, Denise M Adams3,7, Sophie Vadeboncoeur2,3, Marilyn G Liang2,3, Arin K Greene3,8, John B Mulliken3,8, Steven J Fishman3,5. 1. Tufts University School of Medicine, Boston, Massachusetts. 2. Department of Dermatology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Vascular Anomalies Center, Boston Children's Hospital, Boston, Massachusetts. 4. Department of Surgery and Trauma, Eastern Maine Medical Center, Bangor, Maine. 5. Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Division of Vascular and Interventional Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 7. Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 8. Department of Plastic and Oral Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: CLOVES syndrome is associated with somatic mosaic PIK3CA mutations and characterized by congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies. Wilms tumor (WT) is a malignant embryonal renal neoplasm associated with hemihypertrophy and certain overgrowth disorders. After identifying WT in a child with CLOVES, we questioned whether ultrasonographic screening was necessary in these patients. METHODS: We retrospectively reviewed patients with CLOVES syndrome in our Vascular Anomalies Center at Boston Children's Hospital between 1998 and 2016 to identify those who developed WT. A PubMed literature search was also conducted to find other patients with both conditions. RESULTS: A total of 122 patients with CLOVES syndrome were found in our database (mean age 7.7 years, range 0-53 years). Four patients developed WT; all were diagnosed by 2 years of age. The incidence of WT in our CLOVES patient population (3.3%) was significantly greater than the incidence of WT in the general population (1/10,000) (P < 0.001). Four additional patients with WT and CLOVES syndrome were identified in our literature review. CONCLUSION: Patients with CLOVES syndrome have an increased risk of WT. Given the benefits of early detection and treatment, children with CLOVES syndrome should be considered for quarterly abdominal ultrasonography until age 7 years. Screening may be most beneficial for patients under 3 years of age.
BACKGROUND:CLOVES syndrome is associated with somatic mosaic PIK3CA mutations and characterized by congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies. Wilms tumor (WT) is a malignant embryonal renal neoplasm associated with hemihypertrophy and certain overgrowth disorders. After identifying WT in a child with CLOVES, we questioned whether ultrasonographic screening was necessary in these patients. METHODS: We retrospectively reviewed patients with CLOVES syndrome in our Vascular Anomalies Center at Boston Children's Hospital between 1998 and 2016 to identify those who developed WT. A PubMed literature search was also conducted to find other patients with both conditions. RESULTS: A total of 122 patients with CLOVES syndrome were found in our database (mean age 7.7 years, range 0-53 years). Four patients developed WT; all were diagnosed by 2 years of age. The incidence of WT in our CLOVESpatient population (3.3%) was significantly greater than the incidence of WT in the general population (1/10,000) (P < 0.001). Four additional patients with WT and CLOVES syndrome were identified in our literature review. CONCLUSION:Patients with CLOVES syndrome have an increased risk of WT. Given the benefits of early detection and treatment, children with CLOVES syndrome should be considered for quarterly abdominal ultrasonography until age 7 years. Screening may be most beneficial for patients under 3 years of age.
Authors: Sofia Douzgou; Myfanwy Rawson; Eulalia Baselga; Moise Danielpour; Laurence Faivre; Alon Kashanian; Kim M Keppler-Noreuil; Paul Kuentz; Grazia M S Mancini; Marie-Cecile Maniere; Victor Martinez-Glez; Victoria E Parker; Robert K Semple; Siddharth Srivastava; Pierre Vabres; Marie-Claire Y De Wit; John M Graham; Jill Clayton-Smith; Ghayda M Mirzaa; Leslie G Biesecker Journal: Clin Genet Date: 2021-07-16 Impact factor: 4.296
Authors: Kit San Yeung; Winnie Wan Yee Tso; Janice Jing Kun Ip; Christopher Chun Yu Mak; Gordon Ka Chun Leung; Mandy Ho Yin Tsang; Dingge Ying; Steven Lim Cho Pei; So Lun Lee; Wanling Yang; Brian Hon-Yin Chung Journal: Mol Autism Date: 2017-12-20 Impact factor: 7.509
Authors: Adam Ustaszewski; Joanna Janowska-Głowacka; Katarzyna Wołyńska; Anna Pietrzak; Magdalena Badura-Stronka Journal: Arch Med Sci Date: 2020-02-25 Impact factor: 3.318
Authors: Marta Biderman Waberski; Marjorie Lindhurst; Kim M Keppler-Noreuil; Julie C Sapp; Laura Baker; Karen W Gripp; Denise M Adams; Leslie G Biesecker Journal: Genet Med Date: 2018-01-04 Impact factor: 8.864